Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belotecan vs Topotecan in Relapsed Small Cell Lung Cancer
NCT01497873Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2010
- Primary completion
- Dec 2017
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belotecan in small cell lung cancer (SCLC), sponsored by Chong Kun Dang Holdings. Started Sep 2010; status: completed.
02
Drugs
belotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01497873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497873.